Bucindolol: new hopes from reviewing past data.

Published

Journal Article (Review)

β-Adrenoceptor antagonists or β-blockers are a cornerstone of therapy in chronic heart failure (CHF). Bucindolol hydrochloride is a fourth-generation β-blocker in development for the treatment of CHF. Two trials have been conducted to evaluate its use in CHF, and a third is under way to investigate bucindolol for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population. This review aims to summarize the history, pharmacology and clinical trials of bucindolol.

Full Text

Duke Authors

Cited Authors

  • Fiuzat, M; O'Connor, CM

Published Date

  • May 2011

Published In

Volume / Issue

  • 47 / 5

Start / End Page

  • 347 - 351

PubMed ID

  • 22013565

Pubmed Central ID

  • 22013565

International Standard Serial Number (ISSN)

  • 1699-3993

Digital Object Identifier (DOI)

  • 10.1358/dot.2011.47.5.1579112

Language

  • eng

Conference Location

  • Spain